KIMS to Manage UAIMS Hospital in Sangli Under 7-Year Agreement

Krishna Institute of Medical Sciences Ltd (KIMS) has entered into an operations and management agreement with Ushahkal Abhinav Institute of Medical Sciences (UAIMS) Hospital in Sangli, Maharashtra. The agreement is for an initial period of seven years, with an option to extend it by another three years. 

KIMS will handle the hospital’s management and service operations while retaining exclusive rights over its medical services.

Expansion Plans

UAIMS Hospital, established in 2022, is a quaternary care facility with 316 beds. It has plans to expand beyond 500 beds in the future. The hospital is equipped with CT and MRI facilities, 15 operation theatres, and a mother and child care unit occupying an entire floor. UAIMS has over 100 critical care beds.

As per the filling, a daycare oncology centre is also under development near the hospital. It is expected to be completed and become operational in 2025.

Financial Terms and Rights

As per the agreement, KIMS will receive 9% of UAIMS Hospital’s net revenue. KIMS and its affiliates will also have the first right of refusal (ROFR) to acquire profit-sharing interests from existing partners during the contract period. Additionally, KIMS has a call option to acquire a majority profit share in UAIMS at its discretion.

KIMS’ in Maharashtra

KIMS has been expanding its presence in Maharashtra in recent years. It acquired Kingsway Hospital in Nagpur in 2022 and started operations at its Nashik hospital in 2024. It has also announced a new 300-bed multi-specialty hospital in Thane, which is to begin operations in the next financial year.

Market Impact

On February 18, 2025, shares of Krishna Institute of Medical Sciences Ltd traded at ₹549.00, down ₹12.25 (2.18%) at 12:47 PM. The stock has declined 11.89% over the past month but remains up 23.11% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.